These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36149968)

  • 1. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
    Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
    Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
    Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
    Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
    Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
    Blood; 2023 Apr; 141(14):1675-1684. PubMed ID: 36542826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
    Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
    Future Oncol; 2024; 20(21):1455-1465. PubMed ID: 38547003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
    St-Pierre F; Gordon LI
    Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
    Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
    Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
    Elmacken M; Peredo-Pinto H; Wang C; Xu Z; Tegenge M; Jaigirdar AA; Theoret MR; Purohit-Sheth T; Kasamon YL
    Clin Cancer Res; 2024 Jun; 30(11):2309-2316. PubMed ID: 38324398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
    Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
    Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
    Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
    Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A
    Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
    Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
    Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma.
    Lionel AC; Westin J
    Curr Oncol Rep; 2023 Nov; 25(11):1387-1396. PubMed ID: 37861914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.
    Salles G; Spin P; Liu FF; Garcia J; Kim Y; Hasskarl J
    Adv Ther; 2021 Jun; 38(6):3266-3280. PubMed ID: 33970454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
    Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
    J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
    Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
    Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
    Linhares Y; Freytes CO; Cherry M; Bachier C; Maris M; Hoda D; Varela JC; Bellomo C; Cross S; Essell J; Fanning S; Terebelo H; Yimer H; Courtright J; Sharman JP; Kostic A; Vedal M; Ogasawara K; Avilion A; Espinola R; Yuan B; Mattar B
    Blood Adv; 2024 Dec; 8(23):6114-6126. PubMed ID: 39347584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
    Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J
    Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.